Fergie, six-time Grammy Award winner and Avon spokesperson, was a special guest at the eighth annual Los Angeles-area Avon Walk for Breast Cancer in Santa Barbara, CA, on September 11-12. The Avon Walk raised more than $6.4 million to advance access to care and breast cancer research, and attracted more than 2,800 participants from 45 states and Canada, including 322 breast cancer survivors.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/avon/42977/
Fergie, eight-time Grammy Award winner and global ambassador for the Avon Foundation for Women, was a special guest at the tenth annual Southern California Avon Walk for Breast Cancer in Santa Barbara, CA, on September 22-23. The Avon Walk Santa Barbara, the seventh of nine Avon Walks this year, raised more than $4.7 million to advance access to care and breast cancer research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58224-fergie-joins-thousands-at-avon-walk-for-breast-cancer-santa-barbara
Alcatel-Lucent (Euronext Paris and NYSE: ALU) today announced a major advance to its global leadership in 100G optical networking by introducing a breakthrough in single-carrier coherent technology that will extend optical signals over distances far greater than has been possible before, even over poor quality fiber. This latest addition to the company’s portfolio is designed to enhance the ability of communications service providers to address exploding demand for high-bandwidth services like video and fixed and mobile broadband.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53498-alcatel-lucent-expands-100g
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
It’s an all too common tragedy: beloved pets lost or abandoned in the wake of a disaster. The Insurance Information Institute recommends that everyone have a disaster plan, but if you have pets, advance planning is key.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/insuranceinformationinstitute/51010/
Unprecedented planning by state and local authorities, law enforcement and the insurance industry established what is being called a national model for protecting the public from fly-by-night contractors in the aftermath of a natural disaster.
According to the National Insurance Crime Bureau (NICB), preparation in advance of the F-5 tornado that devastated the city of Moore and surrounding areas in May 2013 resulted in a well-coordinated effort to ensure that roofers and other contractors who swarmed into the area in the hours and days after the storm were properly licensed, insured and authorized to work in the area.
Local police assisted the Oklahoma Insurance Department Fraud Unit in patrolling the area and keeping suspected fraudulent out-of-state contractors from doing work unless all protocols were followed.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665251-nicb-limited-fraud-following-2013-moore-tornado/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Crayola today launched its nationwide “COLORCYCLE” marker program, which transforms used markers directly into clean energy. The program is the latest innovation in the company’s continuing commitment to advance its sustainability efforts. The “COLORCYCLE” marker program will allow students to responsibly dispose of any type of used marker through an in-school collection process, keeping plastic out of landfills. Once the used markers are collected, a unique technology will convert the markers into usable fuel.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57862-colorcycle-marker-crayola-clean-energy-program-clean-energy
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Today Concentrix Corporation, a wholly-owned subsidiary of SYNNEX Corporation (NYSE: SNX), announced the addition of 19 delivery locations, across 13 countries, completing the second phase of the acquisition of IBM's global customer care and industry process services business. With over 95% of the acquisition completed, Concentrix continues to advance its position as a leader in the customer care and industry process services market, with over 45,000 employees delivering high value services.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7146451-concentrix-completes-2nd-phase-of-ibm-customer-care-business-acquisition
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
